SCHEMBL22987600

SCHEMBL22987600

COc1ccc(-c2nc3c4cccc(Br)c4nc(N[C@@H]4CN(C(=O)OCc5ccccc5)CCNC4=O)n3n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 5/20 0.40
MMP9 P14780 5/20 0.40
MMP1 P03956 4/20 0.40
MMP3 P08254 4/20 0.40
MMP7 P09237 3/20 0.40
MMP13 P45452 2/20 0.40
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
MAPT P10636 3/20 0.38
THRB P10828 1/20 0.38
ADAM17 P78536 1/20 0.38
ADAM9 Q13443 1/20 0.38
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37
PARP1 P09874 1/20 0.36
MMP2 P08253 1/20 0.36
MMP8 P22894 1/20 0.36
BCL9 O00512 1/20 0.36
CTNNB1 P35222 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22988011 1.00 ADORA3 (0.40) ADORA3MMP9MMP1MMP3MMP7
SCHEMBL29646480 1.00 ADORA3 (0.40) ADORA3MMP9MMP1MMP3MMP7
SCHEMBL22988314 0.93 ADORA3 (0.40) ADORA3MMP9MMP1MMP3MMP7
SCHEMBL22987917 0.93 MAPT (0.42) ADORA3MMP9MMP1MMP3MMP7
SCHEMBL30393181 0.93 ADORA3 (0.40) ADORA3MMP9MMP1MMP3MMP7
SCHEMBL22987627 0.92 ADORA3 (0.40) ADORA3MMP9MMP1MMP3MMP7
SCHEMBL25118867 0.92 ADORA3 (0.40) ADORA3MMP9MMP1MMP3MMP7
SCHEMBL22988108 0.92 TRPC3 (0.39) ADORA3ADORA2AADORA1MAPTKDM1A
SCHEMBL22987799 0.92 TRPC3 (0.39) ADORA3ADORA2AADORA1MAPTKDM1A
SCHEMBL22987722 0.92 TRPC3 (0.39) ADORA3ADORA2AADORA1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114466850-B [1,2,4] Triazolo [1,5-C ] quinazolin-5-amine 拜耳股份有限公司 2024-09-10 CN disclosed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
EP-4013508-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES Bayer Aktiengesellschaft (DE) 2022-06-22 EP disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES AHR, HRH4, HRH1 ADORA3 34/4885MMP9 4726/4885MMP1 4772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.